MedTrace Logo

The Role of Dietary Fat on Postprandial Endotoxemia in Healthy Adults

NCT02521779 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-08-13

No results posted yet for this study

Summary

The purpose of this study was to determine the effect of different dietary fats (saturated or unsaturated) on postprandial endotoxemia and systemic low grade acute inflammation. The investigators hypothesized that meals rich in saturated or n-6 fatty acids would increase postprandial endotoxemia but meals high in n-3 fatty acids would decrease postprandial endotoxemia.Participants were recruited via email and randomized to treatment meal in this single-blind, cross-over study. Each test session participants reported to the laboratory right away in the morning. An indwelling catheter was inserted into the participant non-dominant arm by a qualified nurse and a baseline blood draw was taken. The participant was then provided with one of four test meals (a porridge-type meal containing a different dietary fat), which they ate in entirety within 15 minutes. The participants remained in the laboratory for the next five and a half hours and were not allowed to consume any food or drink except water. During this time, further blood draws were taken at intervals of one hour for a total of five hours after the consumption of the test meal. Collected blood was processed on-site and the serum fraction collected and tested for endotoxin, inflammatory biomarkers, and metabolites.

Conditions

  • Endotoxemia

Interventions

OTHER

Low-fat Treatment Meal

Isocaloric test meal that provided 20% fat.

OTHER

Saturated-fat Treatment Meal

Isocaloric test meal that provided 35% fat with saturated fat (16 g).

OTHER

N-3 fat Treatment Meal

Isocaloric test meal that provided 35% fat with n-3 (DHA = 500mg)

OTHER

N-6 fat Treatment Meal

Isocaloric test meal that provided 35% fat with n-6 (7.4 g).

Sponsors & Collaborators

  • Iowa State University

    lead OTHER

Principal Investigators

  • James H Hollis, PhD · Iowa State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-11-30
Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02521779 on ClinicalTrials.gov